Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
Public ClinicalTrials.gov record NCT01737879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Study identification
- NCT ID
- NCT01737879
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- Peginesatide Drug
- Epoetin alfa Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- Feb 28, 2013
- Completion
- Jun 30, 2013
- Last update posted
- Apr 20, 2014
2012 – 2013
United States locations
- U.S. sites
- 23
- U.S. states
- 13
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85004 | — |
| Research Site | Tempe | Arizona | 85284 | — |
| Research Site | Azusa | California | 91702 | — |
| Research Site | Bakersfield | California | 93309 | — |
| Research Site | Granada Hills | California | 91344 | — |
| Research Site | Los Angeles | California | 90057 | — |
| Research Site | Lynwood | California | 90262 | — |
| Research Site | Paramount | California | 90723 | — |
| Research Site | Riverside | California | 92501 | — |
| Research Site | Whittier | California | 90603 | — |
| Research Site | Orange | Connecticut | 06477 | — |
| Research Site | Meridian | Idaho | 83642 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Bayonne | New Jersey | 07002 | — |
| Research Site | Amherst | New York | 14221 | — |
| Research Site | Yonkers | New York | 10704 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Oklahoma City | Oklahoma | 73116 | — |
| Research Site | Orangeburg | South Carolina | 29118 | — |
| Research Site | Dyersburg | Tennessee | 38024 | — |
| Research Site | Jackson | Tennessee | 38305 | — |
| Research Site | Houston | Texas | 77004 | — |
| Research Site | Chesapeake | Virginia | 23320 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01737879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01737879 live on ClinicalTrials.gov.